Abstract The incidence of MASLD and MASH-associated fibrosis is rapidly increasing worldwide. Drug therapy is hampered by large patient variability and partial representation of human MASH fibrosis in preclinical models. Here. we investigated the mechanisms underlying patient heterogeneity using a discovery dataset and validated in distinct human transcriptomic datasets. http://www.jmannino.com/super-value-NFL-Atlanta-Falcons-Team-Jersey-PS5-Digital-Edition-Bundle-Skin-p121054-great-pick/